Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 59INDUSTRY 14OTHER_GOV 4UNKNOWN 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 33Esophageal Neoplasms 14Stomach Neoplasms 11Rectal Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Triple Negative Breast Neoplasms 8Colorectal Neoplasms 8Small Cell Lung Carcinoma 7Squamous Cell Carcinoma of Head and Neck 6Neoplasm Metastasis 6Lung Neoplasms 6Brain Neoplasms 6Neoplasms 5Esophageal Squamous Cell Carcinoma 5Recurrence 3Nasopharyngeal Carcinoma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma 3Leukemia, Myeloid, Acute 3Hormone Receptor Positive Advanced Breast Cancer 3Head and Neck Neoplasms 3HER2-positive Breast Cancer 3Colonic Neoplasms 3Uterine Cervical Neoplasms 2Sarcoma 2Radiation Injuries 2Papillomavirus Infections 2Carcinoma, Hepatocellular 2Advanced Breast Cancer 2

Interventions

Pemetrexed 1Paclitaxel 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × UNKNOWN × Carcinoma, Squamous Cell × Clear all
NCT03636685 2018-08-17

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

ChineseAMS

Phase 1/2 Unknown
60 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡